Engitix and Morphic Enter Research Collaboration to Identify ECM-related Targets in Fibrostenotic Inflammatory Bowel Disease (IBD)

London, UK and Waltham, Massachusetts, USA – 10 December, 2019 – Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, and Morphic Therapeutic (‘Morphic’), a biopharmaceutical company developing oral integrin therapies, today announce that they have entered into a research […]

Read more

Engitix Receives a Golden Ticket to LabCentral from Takeda to Advance Fibrosis and Solid Tumour Research

Golden Ticket includes one year of lab bench space at Cambridge, MA-based shared laboratory and office space London, UK, 5 November 2019 – Engitix Ltd (‘Engitix’), a private company focused on drug discovery for fibrosis and solid tumours based on its pioneering human extracellular matrix (ECM) platform, announced that its subsidiary Engitix, Inc, has been awarded a Golden Ticket […]

Read more

Engitix Ltd Appoints Gino Van Heeke as Chief Scientific Officer

London, UK, 7 May 2019 – Engitix Ltd, a company pioneering the development of both tissue-specific and disease-specific human extracellular matrix (ECM) for accelerating and improving the drug discovery process, today announces the appointment of Gino Van Heeke, PhD, as Chief Scientific Officer (CSO), effective 7th May. Dr Van Heeke has over 20 years of […]

Read more

UCL Spin-out Engitix Closes £5m Financing to Progress Liver Disease and Pancreatic Cancer Drug Discovery Platform and Pipeline

London, UK, 27 November 2018 – Engitix Ltd, a company pioneering the development of both tissue-specific and disease-specific human extracellular matrix (ECM) for accelerating and improving the drug discovery process, today announces it has closed a £5 million Series A financing, led by a private investor. Engitix has validated its proprietary tissue-specific and disease-specific human […]

Read more